Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma

Chun-Xiao Zhang1, Long-Wei Ye1, Ying Liu1

  • 1Department of Oral Health Sciences, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.

Insights

Newcastle disease virus (NDV) strain D90 effectively induces apoptosis in oral squamous cell carcinoma (OSCC) cells. This avian paramyxovirus also inhibits OSCC cell migration and invasion, offering potential therapeutic strategies for oral cancer.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Newcastle disease virus (NDV) is an avian paramyxovirus with demonstrated oncolytic properties.
  • Oral squamous cell carcinoma (OSCC) is a significant global health concern with limited treatment options.
  • Understanding NDV's mechanisms against OSCC is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To investigate the efficacy of NDV strain D90 against OSCC cells.
  • To elucidate the mechanisms of cell death and metastasis inhibition induced by NDV D90.
  • To evaluate the impact of NDV D90 on OSCC cell migration and invasion.

Main Methods:

  • Cell culture of OSCC cells treated with NDV strain D90.
  • Apoptosis assays (e.g., mitochondrial pathway, death receptor pathway, Bax/Bcl-2 expression).
  • Cell migration and invasion assays, Western blot, and gelatin zymography to assess metastasis-related proteins (sp1, RECK, MMP-2, MMP-9).

Main Results:

  • NDV strain D90 induced apoptosis in OSCC cells via the mitochondrial pathway.
  • NDV D90 inhibited OSCC cell motility by affecting microtubules and microfilaments.
  • NDV D90 significantly reduced OSCC cell invasion and metastasis by modulating sp1, RECK, MMP-2, and MMP-9 expression and activity.

Conclusions:

  • NDV strain D90 exhibits potent oncolytic activity against OSCC cells.
  • NDV D90 effectively suppresses OSCC cell migration and invasion, key factors in metastasis.
  • NDV D90 presents a promising candidate for novel therapeutic strategies in oral cancer treatment.